Preview

Rational Pharmacotherapy in Cardiology

Advanced search

ASSESSMENT OF DIABETES RISK IN MEN WITH DIFFERENT LEVELS OF CARDIOVASCULAR RISK

https://doi.org/10.20996/1819-6446-2012-8-6-766-771

Full Text:

Abstract

Aim. To assess the risk of diabetes mellitus type 2 (DM2) in patients with various cardiovascular (CV) risk, and to identify the relationship between a high risk of DM2 and the major CV risk factors. Material and methods. Men (n=378) with one or more CV risk factors (hypertension of stage 1–3, smoking, hypercholesterolemia) and various CV risk (SCORE) were included in the one- stage clinical trial. All patients were interviewed with standard questionnaire and FINDRISC questionnaire, as well as glucose tolerance test was performed. Results. The patients were split into three groups based on the total CV risk (SCORE): 33.6% had low-to-moderate CV risk, 38.9% — high CV risk and 27.5% — very high CV risk. Most of the men were in the 50–59 and 60–69 years age groups. Most of the patients aged 40–49 years had the high CV risk, while 59% of men aged 50–59 had moderate CV risk. Every second older male had a very high CV risk. According to the FINDRISC questionnaire low risk of DM2 in the next 10 years was detected in 40.2% of patients, intermediate risk — in 35.2%, moderate risk — in 10.3%, high risk — in 11.1%, a very high risk — in 3.2% of patients. Conclusion. Men with very high CV risk (SCORE) have also high and very high risk of DM2 (according to FINDRISC questionnaire). Detection of early markers of glucose metabolism disturbances as well as DM2 risk assessment should be performed in patients with one or more of the above mentioned CV risk factors. This strategy is able to contribute to proper DM2 risk assessment and development of methods of DM2 prevention.

About the Authors

M. N. Kovrigina
State Research Center for Preventive Medicine
Russian Federation


M. N. Mamedov
State Research Center for Preventive Medicine
Russian Federation


References

1. Cardiovascular diseases. Fact sheet number 317. September 2012. Available at: http://www.who.int/mediacentre/factsheets/fs317/en/index.html. Accessed on 10/06/2012.

2. National guidelines for cardiovascular prevention. Kardiovaskulyarnaya Terapiya i Profilaktika 2011; 10 (6) suppl 2: 1–64 Национальные рекомендации по кардиоваскулярной профилактике. Кардиоваскулярная Терапия и Профилактика 2011; 10 (6) Приложение 2: 1–64

3. Bonora E, Targher G, Formentini G et al. The Metabolic Syndrome is an independent predictor of cardiovascular disease in Type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study. Diabet Med 2004;21(1):52–8.

4. Mamedov M.N., Poddubskaya E.A. Early diagnosis and treatment of disorders of glucose metabolism in the therapeutic practice (guidelines). Moscow: GNITs PM; 2011. Russian (Мамедов М.Н., Поддубская Е.А. Диагностика и лечение ранних нарушений углеводного обмена в общетерапевтической практике (методические рекомендации). М.: ГНИЦ ПМ; 2011).

5. Kahn C.R. Diabetes. Causes of insulin resistance. Nature 1995;373(6513):384–5.

6. National guidelines for the diagnosis and treatment of metabolic syndrome. Kardiovaskulyarnaya Terapiya i Profilaktika 2007; 6(6) suppl 2: 1–26. Russian (Национальные рекомендации по диагностике и лечению метаболического синдрома. Кардиоваскулярная Терапия и Профилактика 2007; 6(6) приложение 2: 1–26).

7. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J Suppl 2007; 9 (suppl C): C3–C74.

8. Bozorgmanesh M, Hadaegh F, Sheikholeslami F et al. Shadow of diabetes over cardiovascular disease: comparative quantification of population-attributable all-cause and cardiovascular mortality. Cardiovasc Diabetol 2012;11:69.

9. Toeller M, Buyken AE, Heitkamp G Fiber intake, serum cholesterol levels, and cardiovascular disease in European individuals with type 1 diabetes. EURODIAB IDDM Complications Study Group. Diabetes Care 1999;22 Suppl 2:B21–8.

10. The DECODE Study Group. Gender difference in all-cause and cardiovascular mortality related to hyperglaemia and newly-diagnosed diabetes. Diabetologia 2003; 46: 608–17.

11. Daly CA, Clemens F, Sendon JL, et al.; Euro Heart Survey Investigators. The initial management of stable angina in Europe, from the Euro Heart Survey: a description of pharmacological management and revascularization strategies initiated within the first month of presentation to a cardiologist in the Euro Heart Survey of Stable Angina. Eur Heart J 2005;26(10):1011–22.

12. Schwarz P.E., Li J., Reimann M., et al. The Finnish Diabetes Risk Score Is Associated with Insulin Resistance and Progression towards Type 2 Diabetes. J Clin Endocrinol Metab 2009;94(3):920–926.

13. The DECODE (Тhe Diabetes Epidemiology: Collaborative Analysis of Diagnostic Critera in Europe) Study Group. Glugose tolerance and mortality: comparison off WHO and ADA diagnostic criteria. Lancet 1999; 354: 617–621.


For citation:


Kovrigina M.N., Mamedov M.N. ASSESSMENT OF DIABETES RISK IN MEN WITH DIFFERENT LEVELS OF CARDIOVASCULAR RISK. Rational Pharmacotherapy in Cardiology. 2012;8(6):766-771. (In Russ.) https://doi.org/10.20996/1819-6446-2012-8-6-766-771

Views: 275


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)